📰 Contract Testing Development News
Contract Testing Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Contract Testing Development. Real-time updates on events, politics, business and more.
April 25, 2022
/PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...
April 12, 2022
Chimeric Therapeutics Ltd (ASX:CHM) has entered into a strategic manufacturing partnership with WuXi Advanced Therapies, a global contract testing and...
April 12, 2022
MELBOURNE, Australia, April 11, 2022 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX:CHM, “Chimeric”) a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it
March 23, 2022
/PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...
March 8, 2022
/PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing...
March 8, 2022
PHILADELPHIA, March 7, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the laun...
March 8, 2022
/PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing...
March 8, 2022
Press release content from PR Newswire. The AP news staff was not involved in its creation.
March 8, 2022
TESSA™ technology provides a scalable process for manufacturing gene therapies, accelerating the production of large quantities of therapeutic DNA required to treat patients in need.
March 8, 2022
TESSA™ technology provides a scalable process for manufacturing gene therapies, accelerating the production of large quantities of therapeutic DNA required to treat patients in need New data published in Nature Communications supports the benefits of this technology PHILADELPHIA, March 8, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch...